Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.72
AFFX's Cash to Debt is ranked lower than
71% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. AFFX: 0.72 )
Ranked among companies with meaningful Cash to Debt only.
AFFX' s Cash to Debt Range Over the Past 10 Years
Min: 0.19  Med: 1.15 Max: 15.67
Current: 0.72
0.19
15.67
Equity to Asset 0.62
AFFX's Equity to Asset is ranked higher than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. AFFX: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
AFFX' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.53 Max: 0.95
Current: 0.62
0.22
0.95
Interest Coverage 2.53
AFFX's Interest Coverage is ranked lower than
87% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.72 vs. AFFX: 2.53 )
Ranked among companies with meaningful Interest Coverage only.
AFFX' s Interest Coverage Range Over the Past 10 Years
Min: 0.33  Med: 1.89 Max: 2.53
Current: 2.53
0.33
2.53
F-Score: 8
Z-Score: 3.16
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.64
AFFX's Operating margin (%) is ranked higher than
58% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. AFFX: 4.64 )
Ranked among companies with meaningful Operating margin (%) only.
AFFX' s Operating margin (%) Range Over the Past 10 Years
Min: -59.12  Med: -4.51 Max: 4.64
Current: 4.64
-59.12
4.64
Net-margin (%) 2.81
AFFX's Net-margin (%) is ranked higher than
57% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.99 vs. AFFX: 2.81 )
Ranked among companies with meaningful Net-margin (%) only.
AFFX' s Net-margin (%) Range Over the Past 10 Years
Min: -75.06  Med: -3.74 Max: 3.39
Current: 2.81
-75.06
3.39
ROE (%) 3.20
AFFX's ROE (%) is ranked higher than
56% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.45 vs. AFFX: 3.20 )
Ranked among companies with meaningful ROE (%) only.
AFFX' s ROE (%) Range Over the Past 10 Years
Min: -68.27  Med: -3.67 Max: 3.31
Current: 3.2
-68.27
3.31
ROA (%) 1.93
AFFX's ROA (%) is ranked higher than
61% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.96 vs. AFFX: 1.93 )
Ranked among companies with meaningful ROA (%) only.
AFFX' s ROA (%) Range Over the Past 10 Years
Min: -33.34  Med: -2.03 Max: 1.96
Current: 1.93
-33.34
1.96
ROC (Joel Greenblatt) (%) 20.32
AFFX's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. AFFX: 20.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AFFX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -120.45  Med: -2.66 Max: 18.04
Current: 20.32
-120.45
18.04
Revenue Growth (3Y)(%) 2.00
AFFX's Revenue Growth (3Y)(%) is ranked lower than
57% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. AFFX: 2.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AFFX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.6  Med: 4.70 Max: 102.8
Current: 2
-33.6
102.8
» AFFX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

AFFX Guru Trades in Q2 2015

Jim Simons 2,153,623 sh (+59.90%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce 4,000 sh (unchged)
PRIMECAP Management 11,014,740 sh (-0.20%)
Paul Tudor Jones 30,700 sh (-19.63%)
» More
Q3 2015

AFFX Guru Trades in Q3 2015

Steven Cohen 323,600 sh (New)
Joel Greenblatt 49,493 sh (New)
Ken Fisher 352,394 sh (New)
Jim Simons 2,463,923 sh (+14.41%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce 4,000 sh (unchged)
PRIMECAP Management 10,856,540 sh (-1.44%)
Paul Tudor Jones 25,100 sh (-18.24%)
» More
Q4 2015

AFFX Guru Trades in Q4 2015

Ken Fisher 379,737 sh (+7.76%)
PRIMECAP Management 10,897,740 sh (+0.38%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Jim Simons 2,246,623 sh (-8.82%)
Steven Cohen 128,000 sh (-60.44%)
» More
Q1 2016

AFFX Guru Trades in Q1 2016

Murray Stahl 104,000 sh (unchged)
Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 116.75
AFFX's P/E(ttm) is ranked lower than
96% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.31 vs. AFFX: 116.75 )
Ranked among companies with meaningful P/E(ttm) only.
AFFX' s P/E(ttm) Range Over the Past 10 Years
Min: 11.36  Med: 59.62 Max: 971
Current: 116.75
11.36
971
Forward P/E 30.67
AFFX's Forward P/E is ranked lower than
79% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.92 vs. AFFX: 30.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 127.36
AFFX's PE(NRI) is ranked lower than
96% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.12 vs. AFFX: 127.36 )
Ranked among companies with meaningful PE(NRI) only.
AFFX' s PE(NRI) Range Over the Past 10 Years
Min: 11.71  Med: 61.09 Max: 971
Current: 127.36
11.71
971
Price/Owner Earnings (ttm) 38.38
AFFX's Price/Owner Earnings (ttm) is ranked lower than
53% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.08 vs. AFFX: 38.38 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AFFX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.69  Med: 22.70 Max: 242.42
Current: 38.38
3.69
242.42
P/B 3.32
AFFX's P/B is ranked lower than
54% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. AFFX: 3.32 )
Ranked among companies with meaningful P/B only.
AFFX' s P/B Range Over the Past 10 Years
Min: 0.24  Med: 1.93 Max: 11.78
Current: 3.32
0.24
11.78
P/S 3.27
AFFX's P/S is ranked lower than
52% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. AFFX: 3.27 )
Ranked among companies with meaningful P/S only.
AFFX' s P/S Range Over the Past 10 Years
Min: 0.38  Med: 1.70 Max: 11.2
Current: 3.27
0.38
11.2
PFCF 46.09
AFFX's PFCF is ranked lower than
70% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.30 vs. AFFX: 46.09 )
Ranked among companies with meaningful PFCF only.
AFFX' s PFCF Range Over the Past 10 Years
Min: 1.83  Med: 15.69 Max: 508.54
Current: 46.09
1.83
508.54
POCF 32.36
AFFX's POCF is ranked lower than
73% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.11 vs. AFFX: 32.36 )
Ranked among companies with meaningful POCF only.
AFFX' s POCF Range Over the Past 10 Years
Min: 1.57  Med: 18.63 Max: 6642.5
Current: 32.36
1.57
6642.5
EV-to-EBIT 66.67
AFFX's EV-to-EBIT is ranked lower than
92% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.72 vs. AFFX: 66.67 )
Ranked among companies with meaningful EV-to-EBIT only.
AFFX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1002  Med: 3.55 Max: 721.4
Current: 66.67
-1002
721.4
EV-to-EBITDA 29.62
AFFX's EV-to-EBITDA is ranked lower than
83% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.76 vs. AFFX: 29.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
AFFX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -128.8  Med: 17.50 Max: 112.9
Current: 29.62
-128.8
112.9
Current Ratio 3.78
AFFX's Current Ratio is ranked higher than
64% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. AFFX: 3.78 )
Ranked among companies with meaningful Current Ratio only.
AFFX' s Current Ratio Range Over the Past 10 Years
Min: 1.52  Med: 5.47 Max: 20.23
Current: 3.78
1.52
20.23
Quick Ratio 2.99
AFFX's Quick Ratio is ranked higher than
61% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. AFFX: 2.99 )
Ranked among companies with meaningful Quick Ratio only.
AFFX' s Quick Ratio Range Over the Past 10 Years
Min: 1.33  Med: 4.99 Max: 19.89
Current: 2.99
1.33
19.89
Days Inventory 147.03
AFFX's Days Inventory is ranked lower than
74% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. AFFX: 147.03 )
Ranked among companies with meaningful Days Inventory only.
AFFX' s Days Inventory Range Over the Past 10 Years
Min: 113.05  Med: 140.46 Max: 159.76
Current: 147.03
113.05
159.76
Days Sales Outstanding 59.82
AFFX's Days Sales Outstanding is ranked higher than
53% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.42 vs. AFFX: 59.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
AFFX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.04  Med: 60.74 Max: 80.55
Current: 59.82
49.04
80.55
Days Payable 30.49
AFFX's Days Payable is ranked lower than
75% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.01 vs. AFFX: 30.49 )
Ranked among companies with meaningful Days Payable only.
AFFX' s Days Payable Range Over the Past 10 Years
Min: 23.39  Med: 34.71 Max: 65.81
Current: 30.49
23.39
65.81

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 21.89
AFFX's Price/Net Current Asset Value is ranked lower than
83% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.07 vs. AFFX: 21.89 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AFFX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.9  Med: 12.12 Max: 120.06
Current: 21.89
1.9
120.06
Price/Tangible Book 13.74
AFFX's Price/Tangible Book is ranked lower than
85% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.31 vs. AFFX: 13.74 )
Ranked among companies with meaningful Price/Tangible Book only.
AFFX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.87  Med: 9.60 Max: 73.66
Current: 13.74
0.87
73.66
Price/Projected FCF 2.04
AFFX's Price/Projected FCF is ranked lower than
51% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. AFFX: 2.04 )
Ranked among companies with meaningful Price/Projected FCF only.
AFFX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.42  Med: 1.34 Max: 27.07
Current: 2.04
0.42
27.07
Price/Median PS Value 1.92
AFFX's Price/Median PS Value is ranked lower than
88% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. AFFX: 1.92 )
Ranked among companies with meaningful Price/Median PS Value only.
AFFX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 2.61 Max: 23.18
Current: 1.92
0.32
23.18
Price/Graham Number 8.81
AFFX's Price/Graham Number is ranked lower than
91% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. AFFX: 8.81 )
Ranked among companies with meaningful Price/Graham Number only.
AFFX' s Price/Graham Number Range Over the Past 10 Years
Min: 2.44  Med: 5.55 Max: 8.02
Current: 8.81
2.44
8.02
Earnings Yield (Greenblatt) (%) 1.50
AFFX's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. AFFX: 1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AFFX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.80 Max: 526.4
Current: 1.5
0.1
526.4
Forward Rate of Return (Yacktman) (%) -11.13
AFFX's Forward Rate of Return (Yacktman) (%) is ranked lower than
91% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.85 vs. AFFX: -11.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AFFX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -25.5  Med: 2.70 Max: 12.2
Current: -11.13
-25.5
12.2

More Statistics

Revenue(Mil) $360
EPS $ 0.12
Beta-0.70
Short Percentage of Float17.83%
52-Week Range $8.28 - 16.15
Shares Outstanding(Mil)80.54

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 375 389 404
EPS($) 0.43 0.46 0.50
EPS without NRI($) 0.43 0.46 0.50

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:MYGN, SZSE:300463, TSE:4544, NAS:CPHD, NAS:NEOG, NAS:KANG » details
Traded in other countries:AFF.Germany,
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
» More Articles for AFFX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: PXLW, NGPC, MS, CHMT, AFFX Aug 15 2011 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 5,000 Shares Nov 19 2010 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 10,000 Shares Aug 24 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Jul 31 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Solarwinds Inc., PDL BioPharma, Autobytel Inc., Affymetrix May 08 2010 
Affymetrix Inc. Reports Operating Results (10-Q) May 06 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Affymetrix, Richardson Electronics, First Defiance Financi May 02 2010 
Weekly CEO Buys Highlight: ScheringPlough Corp., Novellus Systems Inc., SeaBright Insurance Holdings May 01 2008 

More From Other Websites
Thermo Fisher Demonstrates Impressive Quarter Apr 28 2016
Thermo Fisher posts higher profit, revenue; raises forecast Apr 28 2016
U.S. companies skeptical of corporate China's advances Apr 27 2016
Inside Thermo Fisher’s Affymetrix Acquisition: A Growth Gauge Apr 07 2016
Thermo Fisher Steals Affymetrix Deal, Expands Antibody Line Apr 04 2016
[$$] What China Bidders Can Learn From Past Week’s Failed Deals Apr 01 2016
Dealpolitik: Lessons for Chinese Bidders in Starwood, Affymetrix Deals Apr 01 2016
AFFYMETRIX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Mar 31 2016
Thermo Fisher (TMO) Completes Affymetrix Deal, Jim Cramer: 'Happy to Move Past The Noise' Mar 31 2016
Thermo Fisher Scientific Completes Acquisition of Affymetrix Following Approval of Transaction by... Mar 31 2016
Thermo Fisher Scientific Completes Acquisition of Affymetrix Following Approval of Transaction by... Mar 31 2016
WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600 Mar 30 2016
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Affymetrix, Inc. Mar 30 2016
Thermo Fisher to Acquire Affymetrix, Origin's Bid Falls Flat Mar 29 2016
Affymetrix (AFFX) Stock Retreats After Origin Withdraws Takeover Bid Mar 29 2016
Affymetrix, Inc. breached its 50 day moving average in a Bearish Manner : AFFX-US : March 29, 2016 Mar 29 2016
Affymetrix recommends against Origin deal, citing China concerns Mar 28 2016
Origin withdraws offer to buy Affymetrix Mar 28 2016
Affymetrix backs Thermo Fisher deal, says rival bid not superior Mar 28 2016
Thermo Fisher Scientific Agrees with Affymetrix that Merger Agreement Remains Superior Mar 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK